328 related articles for article (PubMed ID: 32282100)
21. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
[TBL] [Abstract][Full Text] [Related]
22. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Cortes JE; Goldberg SL; Feldman EJ; Rizzeri DA; Hogge DE; Larson M; Pigneux A; Recher C; Schiller G; Warzocha K; Kantarjian H; Louie AC; Kolitz JE
Cancer; 2015 Jan; 121(2):234-42. PubMed ID: 25223583
[TBL] [Abstract][Full Text] [Related]
23. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F
Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416
[TBL] [Abstract][Full Text] [Related]
24. Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes.
Triesel K; Chiang T; Seabury R; Miller C
J Oncol Pharm Pract; 2021 Sep; 27(6):1539-1541. PubMed ID: 33307969
[TBL] [Abstract][Full Text] [Related]
25. Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
Wang Q; Banerjee K; Vasilinin G; Marier JF; Gibbons JA
J Clin Pharmacol; 2019 May; 59(5):748-762. PubMed ID: 30566230
[TBL] [Abstract][Full Text] [Related]
26. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
27. Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alotaibi S; Niederwieser D; Ahmed SO; Sanz J; Mohty M; Aljurf M
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):575-580. PubMed ID: 35418351
[TBL] [Abstract][Full Text] [Related]
28. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G
Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.
Cortes JE; Lin TL; Asubonteng K; Faderl S; Lancet JE; Prebet T
J Hematol Oncol; 2022 Oct; 15(1):155. PubMed ID: 36289532
[TBL] [Abstract][Full Text] [Related]
30. Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia.
Villa KF; Ryan RJ; Chiarella M; Louie AC
J Med Econ; 2020 Jul; 23(7):714-720. PubMed ID: 32188326
[No Abstract] [Full Text] [Related]
31. Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia.
Kasner MT
Clin Adv Hematol Oncol; 2019 Nov; 17(11):604-606. PubMed ID: 31851160
[No Abstract] [Full Text] [Related]
32. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
33. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
[TBL] [Abstract][Full Text] [Related]
34. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
[TBL] [Abstract][Full Text] [Related]
35. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
Röllig C; Kramer M; Gabrecht M; Hänel M; Herbst R; Kaiser U; Schmitz N; Kullmer J; Fetscher S; Link H; Mantovani-Löffler L; Krümpelmann U; Neuhaus T; Heits F; Einsele H; Ritter B; Bornhäuser M; Schetelig J; Thiede C; Mohr B; Schaich M; Platzbecker U; Schäfer-Eckart K; Krämer A; Berdel WE; Serve H; Ehninger G; Schuler US;
Ann Oncol; 2018 Apr; 29(4):973-978. PubMed ID: 29390048
[TBL] [Abstract][Full Text] [Related]
36. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
[TBL] [Abstract][Full Text] [Related]
37. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
Lin TL; Newell LF; Stuart RK; Michaelis LC; Rubenstein E; Pentikis HS; Callahan T; Alvarez D; Liboiron BD; Mayer LD; Wang Q; Banerjee K; Louie AC
Cancer Chemother Pharmacol; 2019 Jul; 84(1):163-173. PubMed ID: 31098682
[TBL] [Abstract][Full Text] [Related]
38. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
39. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
Lin TL; Rizzieri DA; Ryan DH; Schiller GJ; Kolitz JE; Uy GL; Hogge DE; Solomon SR; Wieduwilt MJ; Ryan RJ; Faderl S; Cortes JE; Lancet JE
Blood Adv; 2021 Mar; 5(6):1719-1728. PubMed ID: 33724305
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
Wang H; Mao L; Yang M; Qian P; Lu H; Tong H; Xie W; Zhou D; Huang X; Wang Y; Xu G; Lu Y; Wei J; Mai W; Ye X; Meng H; Shen Y; Huang J; Yu W; Sun J; Sheng J; Yan X; Jin J; Zhu HH
Lancet Haematol; 2022 Jun; 9(6):e415-e424. PubMed ID: 35512726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]